Scarica l'app Stockscreener
33.27
1.00%
0.33
Dopo l'orario di chiusura:
33.42
0.15
+0.45%
Precedente Chiudi:
$32.94
Aprire:
$33.2
Volume 24 ore:
1.40M
Relative Volume:
0.58
Capitalizzazione di mercato:
$4.57B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-7.2326
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
+0.54%
1M Prestazione:
-5.00%
6M Prestazione:
-60.06%
1 anno Prestazione:
-56.26%
Intervallo 1D:
$33.10
$34.41
Intervallo di 1 settimana:
$32.00
$34.63
Portata 52W:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Confronta PCVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
33.27 | 4.57B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Vaxcyte Holds Annual Stockholders Meeting on Governance - TipRanks
How To Trade (PCVX) - news.stocktradersdaily.com
Here’s Why Vaxcyte (PCVX) Sold Off in Q1 - MSN
Transcript : Vaxcyte, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - MarketScreener
Vaxcyte: Sentiment Is Pushing The Shares Down (NASDAQ:PCVX) - Seeking Alpha
Cantor Fitzgerald maintains Overweight on Vaxcyte shares By Investing.com - Investing.com Canada
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Buy” by Analysts - Defense World
(PCVX) Long Term Investment Analysis - news.stocktradersdaily.com
Head to Head Contrast: Vaxcyte (NASDAQ:PCVX) and Beam Therapeutics (NASDAQ:BEAM) - Defense World
Vaxcyte (VCYT) Jumps Over 4.5%: Is This Biotech Eyeing a Return Towards Its $121 High? - Daily Chhattisgarh News
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking the 286% Potential Upside for Investors - DirectorsTalk Interviews
How the (PCVX) price action is used to our Advantage - news.stocktradersdaily.com
James T. Wassil ’99G ’05G of Vaxcyte Inc., Tells Graduates ‘The Journey Ahead is Yours to Shape’ - Lehigh University
Transcript : Vaxcyte, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Research Analysts Set Expectations for Vaxcyte Q3 Earnings - Defense World
Leerink Partnrs Brokers Cut Earnings Estimates for Vaxcyte - Defense World
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? - MSN
Vaxcyte, Inc. Reports Q1 2025 Financial Results - TipRanks
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight - GuruFocus
Vaxcyte (PCVX) Advances Pneumococcal Vaccine Development | PCVX Stock News - GuruFocus
Vaxcyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Vaxcyte Inc Reports Q1 2025 EPS of -$1.04, Beating Estimates; Net Loss Widens to $140.7 Million - GuruFocus
Oversold Conditions For Vaxcyte (PCVX) - Nasdaq
Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
Vaxcyte appoints new independent director - Investing.com Australia
Vaxcyte appoints new independent director By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board - TipRanks
Vaxcyte adds former Sanofi CEO to its board - Investing.com
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - The Manila Times
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? - Yahoo Finance
11 Oversold NASDAQ Stocks to Buy Right Now - Insider Monkey
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
PCVXVaxcyte, Inc. Latest Stock News & Market Updates - Stock Titan
James T. Wassil ’99G ’05G of Vaxcyte, Inc. Named Lehigh’s 2025 Graduate Commencement and Doctoral Hooding Ceremony Speaker - Lehigh University
Vaxcyte (PCVX) Gains Attention with Overweight Rating Amid Marke - GuruFocus
Vaxcyte (PCVX) Gains Attention with Overweight Rating Amid Market Shifts | PCVX Stock News - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz | PCVX Stock News - GuruFocus
Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options - Nasdaq
TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX) - The Globe and Mail
When the Price of (PCVX) Talks, People Listen - news.stocktradersdaily.com
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340% - The Globe and Mail
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vaxcyte Inc Azioni (PCVX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):